This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEI9H0FH_L.jpg
(Reuters) – Drugmaker Eli Lilly (NYSE:LLY) and Co will acquire genetic medicine developer Akouos Inc in a cash deal worth about $487 million.
Lilly will also pay Akouos’ shareholders an additional amount of about $610 million contingent on certain events related to its trials.
